Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Status:
Not yet recruiting
Trial end date:
2024-11-20
Target enrollment:
Participant gender:
Summary
Widespread recognition of the current and projected impact of the dementia epidemic has
spurred research into novel drug discovery efforts. It is well recognized by most that
Alzheimer's disease is not the only form of dementia and that beginning to turn attention to
other disease states is critically important in order to alleviate this burden on the elderly
population today This proposal seeks to further progress in this area through the repurposing
an existing drug therapy as a potential treatment for Hippocampal Sclerosis of Aging. This
disease is seldom recognized clinically and yet is the number one Alzheimer's disease mimic
the confounds are diagnostic and treatment of subjects suffering from dementia and as of yet
has no potential therapeutic interventions identified. As such, the proposed study represents
a cutting-edge, data-driven, low-cost, exploration of a novel disease relevant pathway that
may hold promise for global efforts targeting late life dementia which is a major health
priority in America today.